A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease

Inclusion Criteria:

• Biopsy report indicative of primary FSGS or primary MCD, with supportive clinicalpresentation per Investigator's judgement.

• UPCR ≥3 g/g at screening, or ≥ 1.5 g/g in those with eGFR ≥ 60.

• eGFR ≥45 mL/min/1.73 m^2 at screening.

• Documented history of UPCR (or 24-hour urine protein) reduction by >40% in responseto corticosteroid or other immunosuppressive therapy when pre-treatment UPCR was ≥3.5 g/g (or pre-treatment 24-hr urine protein was ≥3.5 g/day if 24-hour urineprotein is used).

• ≤10 mg/day prednisone or equivalent and stable starting at least 1 week prior torandomization.

• For those on a RAAS inhibitor prior to screening, the dose must be stable ≥4 weeksprior to screening; starting RAAS inhibitors or changing the dose will not beallowed during the double-blind or OLE treatment period.

• For those on an SGLT2 inhibitor prior to screening, the dose must be stable ≥4 weeksprior to screening; starting SGLT2 inhibitor treatment or changing the dose will notbe allowed during the double-blind or OLE treatment periods.

• Body weight within 45 to 120 kg (inclusive) at screening.

Exclusion Criteria:

• Genetic or secondary FSGS or MCD. Those with APOL1 risk alleles are eligible.

• Collapsing variant of FSGS.

• ESKD requiring dialysis or transplantation.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.